A carregar...

Gefitinib and Methotrexate to Treat Ectopic Pregnancies with a Pre-Treatment Serum hCG 1000–10,000 IU/L: Phase II Open Label, Single Arm Multi-Centre Trial()

BACKGROUND: Ectopic pregnancies are a leading cause of maternal mortality. Most are treated surgically. We evaluated the efficacy and safety of combining oral gefitinib (epidermal growth factor receptor inhibitor) with methotrexate to treat larger ectopic pregnancies. METHODS: We performed a phase I...

ver descrição completa

Na minha lista:

Detalhes bibliográficos
Publicado no:	EBioMedicine
Main Authors:	Skubisz, Monika M., Tong, Stephen, Doust, Ann, Mollison, Jill, Johns, Terrance G., Neil, Peter, Robinson, Miranda, Bhattacharya, Siladitya, Wallace, Euan, Krzys, Nicole, Colin Duncan, W., Horne, Andrew W.
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2018
Assuntos:	Research Paper
Acesso em linha:	https://ncbi.nlm.nih.gov/pmc/articles/PMC6085507/ https://ncbi.nlm.nih.gov/pubmed/29941341 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2018.06.017
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!

Gefitinib and Methotrexate to Treat Ectopic Pregnancies with a Pre-Treatment Serum hCG 1000–10,000 IU/L: Phase II Open Label, Single Arm Multi-Centre Trial()

Registos relacionados

Gefitinib and Methotrexate to Treat Ectopic Pregnancies with a Pre-Treatment Serum hCG 1000–10,000 IU/L: Phase II Open Label, Single Arm Multi-Centre Trial()